15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Somatostatin-based radiopeptide therapy with [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC in neuroendocrine tumours.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Somatostatin-based radiopeptide treatment is generally performed using the β-emitting radionuclides (90)Y or (177)Lu. The present study aimed at comparing benefits and harms of both therapeutic approaches.

          Related collections

          Author and article information

          Journal
          Eur. J. Nucl. Med. Mol. Imaging
          European journal of nuclear medicine and molecular imaging
          1619-7089
          1619-7070
          Feb 2014
          : 41
          : 2
          Affiliations
          [1 ] Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
          Article
          10.1007/s00259-013-2559-8
          24085501
          83fd5b7e-ad26-42e0-a3bd-3b59eb057a6d
          History

          Comments

          Comment on this article